NCT01796197View on ClinicalTrials.gov

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

November 30, 2025

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

DRUG

Pertuzumab

DRUG

Paclitaxel

DRUG

Doxorubicin

DRUG

Cyclophosphamide

PROCEDURE

Mastectomy

RADIATION

Radiation Therapy

Trial Locations (3)

48109

University of Michigan, Ann Arbor

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER